Congenital Sucrase-Isomaltase Deficiency clinical trials at UCSF

1 research study open to eligible people

Congenital sucrase-isomaltase deficiency means the body can't digest some sugars properly. UCSF is running a trial to see if a 7-day Sucraid treatment can relieve symptoms in people with low, moderate, or normal sucrase levels. The study is being conducted in multiple U.S. locations.

Showing trials for

  • 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

    open to eligible people ages 6 months to 17 years

    This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).

    Oakland, California and other locations

Last updated: